Literature DB >> 20671821

Causes and management of drug-induced long QT syndrome.

Ramy F Ayad1, Manish D Assar, Leo Simpson, John B Garner, Jeffrey M Schussler.   

Abstract

Long QT syndrome (LQTS) is characterized by inherited or acquired prolonged QT interval on the surface electrocardiogram. This can lead to torsade de pointes ventricular tachycardia (TdP VT) and ventricular fibrillation. In the acquired form of the disease, medications from several classes can cause TdP VT or potentiate the electrocardiographic findings. These include class IA and III antiarrhythmics, antibiotics (macrolides and quinolones), antidepressants (tricyclics and selective serotonin reuptake inhibitors), antipsychotics (haloperidol and phenothiazines), and antiemetics (ondansetron and prochlorperazine). We present four cases of drug-induced LQTS resulting in life-threatening cardiac arrhythmias. Antiarrhythmic medications were the cause in two cases, and the other two cases involved noncardiac medications. All four patients had at least one risk factor for LQTS in addition to the offending drug, including female gender, hypokalemia, hypomagnesemia, and bradycardia. In one patient, amiodarone was administered for treatment of VT, although the correct diagnosis was actually TdP VT. In patients with polymorphic VT or ventricular fibrillation without a significant history of cardiovascular disease, drug-induced LQTS should be high in the differential diagnosis. Prompt diagnosis is key, as amiodarone, while often used to suppress VT, is potentially harmful in the setting of LQTS and TdP VT.

Entities:  

Year:  2010        PMID: 20671821      PMCID: PMC2900977          DOI: 10.1080/08998280.2010.11928628

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  14 in total

1.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2008-05-15       Impact factor: 29.690

2.  Taking the "idio" out of "idiosyncratic": predicting torsades de pointes.

Authors:  D M Roden
Journal:  Pacing Clin Electrophysiol       Date:  1998-05       Impact factor: 1.976

3.  Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.

Authors:  Alexander N Katchman; John Koerner; Toshimasa Tosaka; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2005-11-08       Impact factor: 4.030

Review 4.  Magnesium: nature's physiologic calcium blocker.

Authors:  L T Iseri; J H French
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

Review 5.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

Review 6.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

Review 8.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

9.  Afterdepolarizations as a mechanism for the long QT syndrome: electrophysiologic studies of a case.

Authors:  E Schechter; C C Freeman; R Lazzara
Journal:  J Am Coll Cardiol       Date:  1984-06       Impact factor: 24.094

10.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.

Authors:  T Yang; D M Roden
Journal:  Circulation       Date:  1996-02-01       Impact factor: 29.690

View more
  11 in total

1.  Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.

Authors:  Özlem Önen; Ayşe Kutlu; Handan Özek Erkuran
Journal:  Psychopharmacol Bull       Date:  2017-01-26

2.  Secondly ECG recordings in the emergency room revealed Garenoxacin-induced abnormal QT interval prolongation in a patient with multiple syncopal attacks.

Authors:  Minoru Tagawa; Sachie Ochiai; Yuichi Nakamura; Akinori Sato; Masaomi Chinushi
Journal:  Heart Vessels       Date:  2015-05-29       Impact factor: 2.037

3.  Drug-Induced Long-QT and Torsades de Pointes in Elderly Polymedicated Patients.

Authors:  Daniel García-Fuertes; Elena Villanueva-Fernández; Manuel Crespín-Crespín
Journal:  Arq Bras Cardiol       Date:  2016-02       Impact factor: 2.000

4.  Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.

Authors:  G Michels; M Kochanek; R Pfister
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

Review 5.  Approach to Acute Cardiovascular Complications in COVID-19 Infection.

Authors:  Lauren S Ranard; Justin A Fried; Marwah Abdalla; D Edmund Anstey; Raymond C Givens; Deepa Kumaraiah; Susheel K Kodali; Koji Takeda; Dimitrios Karmpaliotis; LeRoy E Rabbani; Gabriel Sayer; Ajay J Kirtane; Martin B Leon; Allan Schwartz; Nir Uriel; Amirali Masoumi
Journal:  Circ Heart Fail       Date:  2020-06-05       Impact factor: 8.790

Review 6.  Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach.

Authors:  Matisyahu Shulman; Avraham Miller; Jason Misher; Aleksey Tentler
Journal:  J Multidiscip Healthc       Date:  2014-10-31

7.  Q-T interval prolongation in cirrhosis: Relationship and severity.

Authors:  Ali-Akbar Hajiaghamohammadi; Mohammad-Mahdi Daee; Ali Zargar; Somayeh Ahmadi-Gooraji; Alfred Rahban; Fereshte Attaran
Journal:  Caspian J Intern Med       Date:  2018

Review 8.  Acquired long QT syndrome in chronic kidney disease patients.

Authors:  Peng Liu; Lu Wang; Dan Han; Chaofeng Sun; Xiaolin Xue; Guoliang Li
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

Review 9.  Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?

Authors:  Shahzad Khan; Sahibzada Tasleem Rasool; Syed Imran Ahmed
Journal:  Curr Probl Cardiol       Date:  2021-03-19       Impact factor: 5.200

10.  Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein.

Authors:  Julie Huiyuan Xiao; Pramila Rijal; Lisa Schimanski; Arun Kumar Tharkeshwar; Edward Wright; Wim Annaert; Alain Townsend
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.